| P/E (FY) | — | Sales (TTM) | $4.6M |
| Earnings (TTM) | -$198.4M | ROE | −146.81% |
| Net Margin | −4342.44% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Prime Medicine is a biotechnology company developing genetic medicines using gene editing technology in the United States. Its lead candidate is PM359 for chronic granulomatous disease in a Phase 1/2 trial, alongside PM577 for Wilson disease and PM647 for a SERPINA1-related liver disorder, both in preclinical study. The company also runs in vivo liver and cystic fibrosis programs and offers its Prime Editing technology using programmable DNA binding domains.
| Market Cap | $558.1M | Trading Days | 1904 |
| 52W High | 6.94 |
| 52W Low | 2.67 |
| % Off High | −55.48% |
| YTD | −10.95% | 1Y | −24.45% |
| 3Y | −79.18% | 5Y | −79.90% |
| 10Y | −85.58% | Since incept. (ann.) | −16.05% |
Reportable 100%
| Ann. Volatility (1Y) | 89.85% | Ann. Volatility (3Y) | 94.51% |
| Sharpe (1Y) | 0.12 | Sharpe (3Y) | −0.08 |
| Max Drawdown (1Y) | −59.52% | Max Drawdown (3Y) | −92.37% |
| Beta (3Y, vs SPY) | 3.16 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| TECX | Tectonic Therapeutic, Inc. | $562.3M | — |
| ALLO | Allogene Therapeutics, Inc. | $573.0M | — |
| ZURA | Zura Bio Ltd | $526.3M | — |
| EIKN | Eikon Therapeutics, Inc. | $513.8M | — |
| RGNX | REGENXBIO Inc. | $496.3M | — |
| FDMT | 4D Molecular Therapeutics, Inc. | $490.3M | — |
| KYTX | Kyverna Therapeutics, Inc. | $455.4M | — |
| REPL | Replimune Group, Inc. | $449.1M | — |
| CABA | Cabaletta Bio, Inc. | $445.1M | — |
| CADL | Candel Therapeutics, Inc. | $709.3M | — |
| AURA | Aura Biosciences, Inc. |
| $728.9M |
| — |
| DNA | Ginkgo Bioworks Holdings, Inc. | $427.0M | — |
